Clinical trial NCT01751243: Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies
Official title: Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Transplant-Related Hematologic Malignancy
Lead sponsor: Andalusian Network for Design and Translation of Advanced Therapies
Sponsor class: OTHER
Collaborators: name: Iniciativa Andaluza en Terapias Avanzadas
First posted: 2012-12-17
Enrollment: 0
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre, prospective, of cohort of patients who will receive different doses of allo-depleted lymphocytes .

This project joins in this pioneering worldwide initiative with its own technology based on the use of proteasome inhibitors in vitro, which advantages are, over other methods described, the continuing viability of regulatory T cells and the use of a product to generate allo-depletion that, contrary to those reported by other research groups, it does not pose problems from the point of view of its use or toxicity as we employ a drug widely used clinically by intravenous administration.

Detailed description: The main objective of the study is to determine the safety of transplantation of hematopoietic progenitors from haploidentical donor with in vitro allo-depleted lymphocyte infusion.

Secondary objectives:

* To assess the immune reconstitution pre and post-infusion of allo-depleted lymphocytes.
* To analyze the incidence of infections (CMV and aspergillus) post-transplant.
* To analyze the impact of acute and chronic graft-versus-host disease (GVHD).
* To optimize the dose of allo-depleted lymphocytes to reconstitute an immune response against pathogens without causing GVHD.
* To assess the rate of graft and myeloid and platelet engraftment time.
* To assess the rate of relapses, event-free survival and overall survival. It is hoped to recruit 20 clinically evaluable patients for safety purpose.

The inclusion period is not more than 2 ½ years. Study duration shall not exceed three years from the inclusion of the first patient. The minimum follow-up of patients is 6 months after transplantation.

The first 5 patients (group 0) will receive haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes and then in cohorts of 3 patients, infuse +4 post-transplant day at doses of: 1x105 cluster of differentiation 3 (CD3)/kg(group 1), 3x105 CD3/kg (group 2), 5x105 CD3 / kg (group 3), 1x106 CD3/kg (group 4) and 3x106 CD3/kg (group 5).

Donor: it is performed one leukapheresis at least 30 days (4 weeks) prior to the scheduled progenitors infusion (day 0), in order to obtain effector T cells.

Eligibility criteria: Inclusion Criteria:

* Adult patients aged between 16 and 50 years.
* Diagnosed as Hematological malignancy candidates to allogeneic transplant lacking of related or unrelated suitable donor (is more than one Human leukocyte antigen (HLA) mismatched over 8 antigens) and who don't have a cord with an adequate cellularity. The minimum period of search to be able to include the patient in the trial, currently considering the medium to find a suitable donor to be 2 months, it is set to 10 weeks, although in specific situations in which the responsible physician considers that the patient has a high risk of relapse, it may be proceed with inclusion before that period. These cases will be assessed individually with the trial coordinator.

Exclusion Criteria:

* General condition\> Eastern Cooperative Oncology Group (ECOG) scale 2.
* Left Ventricular ejection fraction (LVEF) \<39%.
* Diffusion capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) \<39% of the theoretical values.
* Impaired liver function (total bilirubin higher than 2 mg / dL and / or transaminases higher than 3 times the normal maximum.
* Creatinine clearance \<50 mL / minute.
* Presence of symptomatic heart, liver cirrhosis or chronic active hepatitis.
* Active tuberculosis.
* Serious diseases which prevent chemotherapy treatments.
* Associated neoplasias (active neoplasias which, according to the opinion of the investigator and the sponsor, could jeopardize patient safety).
* Presence of associated psychiatric pathology.
* HIV infection.

Primary outcomes:
measure: Number of adverse events and serious adverse events after allo-depleted lymphocyte infusion in vitro.
timeFrame: 6 months
Secondary outcomes:
measure: Incidence of acute and chronic GVHD
timeFrame: 6 months
Other outcomes:
Locations:
city: Cordoba
country: Spain
facility: University Hospital Reina Sofia
city: Malaga
country: Spain
facility: University Hospital Carlos Haya
city: Salamanca
country: Spain
facility: University Hospital de Salamanca
city: Sevilla
country: Spain
facility: University Hospital Virgen del Rocío
Study officials:
affiliation: University Hospital Virgen del Rocío
name: Jose-Antonio Perez-Simón, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Reina Sofía
name: Antonio Torres, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital de Salamanca
name: Lucía Lopez-Corral, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Carlos Haya
name: Mª Ángeles Cuesta, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: